FOLH1 and neoplasm: This iterative testing approach ensures that subsequent therapeutic decisions -including sequencing taxane-based chemotherapy, radiopharmaceuticals like 177Lu–PSMA-617 in patients with prostate-specific membrane antigen (PSMA)-positive disease, or clinical trial enrollment—remain aligned with the evolving molecular profile of the tumor.